Link Silicon Valley
The fastest way to connect to the people, companies and capital of Silicon Valley
Free 30 Day Trial Account
Sign Up | Log In
My Lists

Perlegen Sciences

2021 Stierlin Court
Mountain View, CA 94043
Website Company Summary Management Team

Management: Joseph H. Lehnen (CFO)
Outside board: Satoru Iino (CSK Venture Capital Executive Director)Carl J. Seiden (Seiden Pharmaceutical Strategies President)David V. Smith (Anergen Former CFO) Martha H. Marsh (Stanford Hospital and Clinics CEO)Brad A. Margus (Perlegen Sciences Vice Chairman) Stephen A. Fodor (Affymetrix co-Founder)John A. Young (HP President)

Business description: Perlegen conducts genetics research and develops products that impact and improve people's lives by employing a proprietary, cost-effective method for rapidly analyzing and comparing entire genomes. This whole genome association study capability enables Perlegen to identify genes that work in concert to cause common diseases and affect the body's response to drugs. Formed in late 2000 as an affiliate of Affymetrix, Inc. (Nasdaq: AFFX), Perlegen is accelerating the development of therapeutics and diagnostics and enabling a new paradigm of high-resolution whole genome scanning. Perlegen Sciences quietly closed operations on Oct. 30, 2009.
Partners include: AffymetrixAstraZenecaBristol-Myers SquibbEli LillyGenentech GlaxoSmithKlineJohnsonAndJohnson Pharmaceutical ResearchMerckPfizer Unilever;  Cancer Research Technology;  Cancer Research UK;  Galileo Genomics;  Max Planck Institute for Developmental Biology;  Mayo Clinic;  National Institute on Drug Abuse;  Pritzker Neuropsychiatric;  RIKEN;  Salk Institute;  The Wellcome Trust Case Control Consortium ;  University of Cambridge

Rounds: 3
Recent fundings: Dec 2005   Mar 2005
Capital raised: 256.0M
Last Round: 50.0M
Ownership: Private  
VCs include: Bain Capital VenturesCSK Venture CapitalMaverick CapitalPresidio PartnersZesiger Capital Group;  Biofrontier Ventures;  Brookside Capital;  BSI SA;  Cape Securities;  Lombard Odier;  MPM BioEquities;  Private Life Biomed;  Sano Ventures;  SBV Life Science Ventures
Angels/other VCs: Alejandro Zaffaroni
Corporate investors: AffymetrixEli LillyPfizer;  Mizuho Securities;  Singapore Economic Development Board;  Unilever Technology Ventures

Last Tweets


Last Mentions

Record updated: Nov 2010
Sector: Biotech
Year Founded: 2000
Rounds: 3
Recent fundings: Dec 2005   Mar 2005
Capital raised: 256.0M
Last Round: 50.0M
Ownership: Private